Early Beta Blocker Administration in STEMI Patients With SCAI B Status

This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit. When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups. During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations. The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.

NCT Number	NCT06967194
Lead Sponsor	Tel-Aviv Sourasky Medical Center
Conditions	ST Segment Elevation Myocardial Infarction (STEMI), Cardiogenic Shock Post Myocardial Infarction
Enrollment	200 participants
Start Date	2025-05-21
Primary Completion	2027-05 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2025-05-28